Brian McMillan (BA, biochemistry, 1989) is currently vice president of Formulation Development and co-founder of CoreRx, Inc. Pharmaceuticals in Tampa, Florida (www.corerxpharma.com). He has twenty-three years of relevant experience in pharmaceutical development at nationally acclaimed laboratories such as Roxane Laboratories, Bausch and Lomb Pharmaceuticals, and MDS Pharma Services.
McMillan specializes in developing multi-layer tablet dosage forms and combination products. He has also worked to develop opthalmics, injectables, solid, semi-solid, and liquid oral capsules and tablets, parentherals, and topical pharmaceuticals over the course of his career. During his time at Bausch and Lomb Pharmaceuticals, McMillan was the lead formulator and process development scientist for RetisertTM, a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye. RetisertTM is the world’s first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Since joining CoreRx, Inc. he has developed formulations for injectable products used to prevent potential pandemic influenzas, over a dozen analgesic oral solution products, and various formulations for both IR and MR mono and multi layer tablet systems.
McMillan holds his BA in biochemistry from The Ohio State University where he also majored in pharmaceutical sciences. In addition to his position at CoreRx, Inc., he is currently an assistant professor of pharmacy at the University of South Florida’s College of Pharmacy teaching pre-formulation and formulation development of various dosage forms. He has also been a keynote speaker on JRS PHARMA’s (the world leader in tablet excipient technology) annual advisory board and has worked with JRS on tablet excipient technology development.
McMillan will earn his MS in pharmacy and pharmaceutical chemistry from the University of Florida in spring 2013.